Insulin initiation and intensification in patients with T2DM for the primary care physician

References

• Centers for Disease Control and Prevention National ambulatory medical care survey: 2004 summary Available from: http://www.cdc.gov/nchs/data/ad/ad374.pdf. Accessed June 15, 2011.
   Google Scholar
• Hayes RP Fitzgerald JT Jacober SJ Primary care physician beliefs about insulin initiation in patients with type 2 diabetes Int J Clin Pract 2008 62 860 868 18393965
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Economic costs of diabetes in the US in 2007 Diabetes Care 2008 31 596 615 18308683
   PubMed Web of Science ®Google Scholar
• Guyton JR Hall JE Insulin, glucagon, and diabetes mellitus Guyton JR Hall JE Textbook of Medical Physiology 11th ed Philadelphia, PA Elsevier Saunders 2006 961 977
   Google Scholar
• Unger J Physiologic insulin replacement therapy Unger J Diabetes Management in Primary Care Philadelphia, PA Wolters Kluwer Lippincott Williams & Wilkins 2007 192 264
   Google Scholar
• Kosaka K Kuzuya T Hagura R Yoshinaga H Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus: the usefulness of decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus Diabet Med 1996 13 S109 S119 8894494
   PubMed Web of Science ®Google Scholar
• Leahy JL Bonner-Weir S Weir GC Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion Diabetes Care 1992 15 442 455 1559411
   PubMed Web of Science ®Google Scholar
• Krssak M Brehm A Bernroider E Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes Diabetes 2004 53 3048 3056 15561933
   PubMed Web of Science ®Google Scholar
• Weir GC Bonner-Weir S Five stages of evolving β-cell dysfunction during progression to diabetes Diabetes 2004 53 Suppl 3 S16 S21 15561905
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Knowler WC Barrett-Connor E Fowler SE Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 2002 346 393 403 11832527
   PubMed Web of Science ®Google Scholar
• Sumner CJ Sheth S Griffin JW Cornblath DR Polydefkis M The spectrum of neuropathy in diabetes and impaired glucose tolerance Neurology 2003 60 108 111 12525727
   PubMed Web of Science ®Google Scholar
• Hartge MM Unger T Kintscher U The endothelium and vascular inflammation in diabetes Diabetes Vasc Dis Res 2007 4 84 88
   PubMedGoogle Scholar
• Ceriello A New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy Diabetes Care 2003 26 1589 1596 12716823
   PubMed Web of Science ®Google Scholar
• Monnier L Mas E Ginet C Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes JAMA 2006 295 1681 1687 16609090
   PubMed Web of Science ®Google Scholar
• Evans JL Goldfine ID Maddux BA Grodsky GM Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes Endocr Rev 2002 23 599 622 12372842
   PubMed Web of Science ®Google Scholar
• Matza LS Boye KS Yurgin N Utilities and disutilities for type 2 diabetes treatment-related attributes Qual Life Res 2007 16 1251 1265 17638121
   PubMed Web of Science ®Google Scholar
• Riddle MC The underuse of insulin therapy in North America Diabetes Metab Res Rev 2002 18 Suppl 3 S42 S49 12324985
   PubMed Web of Science ®Google Scholar
• Meneghini L Koenen C Weng W Selam JL The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes–results of the randomized, controlled PREDICTIVE™ 303 study Diabetes Obes Metab 2007 9 902 913 17924873
   PubMed Web of Science ®Google Scholar
• Gerstein HC Yale J-F Harris SB Issa M Stewart JA Dempsey E A randomized trial of adding insulin glargine vs avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study Diabet Med 2006 23 736 742 16842477
   PubMed Web of Science ®Google Scholar
• Davies M Lavalle-Gonzalez F Storms F Gomis R Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial Diabetes Obes Metab 2008 10 Suppl 2 42 49 18577156
   PubMed Web of Science ®Google Scholar
• Peyrot M Rubin RR Lauritzen T Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study Diabetes Care 2005 28 2673 2679 16249538
   PubMed Web of Science ®Google Scholar
• Cobble ME Peters AL Clinical practice in type 2 diabetes: after metformin and lifestyle, then what? J Fam Pract 2009 58 S7 S14 19891948
   PubMedGoogle Scholar
• Hepburn DA MacLeod KM Pell AC Scougal IJ Frier BM Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin Diabet Med 1993 10 231 237 8485954
   PubMed Web of Science ®Google Scholar
• Holstein A Plaschke A Egberts EH Clinical characterisation of severe hypoglycaemia – a prospective population-based study Exp Clin Endocrinol Diabetes 2003 111 364 369 14520604
   PubMed Web of Science ®Google Scholar
• Leese GP Wang J Broomhall J Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use Diabetes Care 2003 26 1176 1180 12663593
   PubMed Web of Science ®Google Scholar
• Polonsky WH Fisher L Schikman CH Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study Diabetes Care 2011 34 262 267 21270183
   PubMed Web of Science ®Google Scholar
• Masley S Sokoloff J Hawes C Planning group visits for high-risk patients Fam Prac Manag 2000 7 33 37
   PubMedGoogle Scholar
• Holman RR Farmer AJ Davies MJ Three-year efficacy of complex insulin regimens in type 2 diabetes N Engl J Med 2009 361 1736 1747 19850703
   PubMed Web of Science ®Google Scholar
• Rodbard HW Jellinger PS Davidson JA Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 2009 15 540 559 19858063
   PubMed Web of Science ®Google Scholar
• Holman RR Thorne KI Farmer AJ Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes N Engl J Med 2007 357 1716 1730 17890232
   PubMed Web of Science ®Google Scholar
• Monnier L Lapinski H Colette C Contributions of fasting and post-prandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c Diabetes Care 2003 26 881 885 12610053
   PubMed Web of Science ®Google Scholar
• Hollander P Cooper J Bregnhoj J Pedersen CB A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes Clin Ther 2008 30 1976 1987 19108786
   PubMed Web of Science ®Google Scholar
• Raskin P Gylvin T Weng W Chaykin L Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes Diabetes Metab Res Rev 2009 25 542 548 19565569
   PubMed Web of Science ®Google Scholar
• Liebl A Insulin intensification – the rationale and the target Int J Clin Pract Suppl 2009 63 1 5 19751452
   PubMedGoogle Scholar
• Karl DM The use of bolus insulin and advancing insulin therapy in type 2 diabetes Curr Diab Rep 2004 4 352 357 15461900
   PubMedGoogle Scholar
• Ceriello A Oxidative stress and diabetes-associated complications Endocr Pract 2006 12 Suppl 1 60 62 16627383
   PubMedGoogle Scholar
• Unger J Reducing oxidative stress in patients with type 2 diabetes mellitus: a primary care call to action Insulin 2008 3 176 184
   Google Scholar
• Scognamiglio R Negut C de Kreutzenberg SV Tiengo A Avogaro A Effects of different insulin regimes on postprandial myocardial perfusion defects in type 2 diabetic patients Diabetes Care 2006 29 95 100 16373903
   PubMed Web of Science ®Google Scholar
• Aagren M Luo W Moes E Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization J Med Econ 2010 13 16 22 19958212
   PubMedGoogle Scholar
• Luijf YM van Bon AC Hoekstra JB Devries JH Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes Diabetes Care 2010 33 2152 2155 20693354
   PubMed Web of Science ®Google Scholar
• Lankisch MR Ferlinz KC Leahy JL Scherbaum WA Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs Diabetes Obes Metab 2008 10 1178 1185 19040645
   PubMed Web of Science ®Google Scholar
• Basu A Man CD Basu R Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism Diabetes Care 2009 32 866 872 19196896
   PubMed Web of Science ®Google Scholar
• Unger J Diagnosis and management of type 2 diabetes and prediabetes Prim Care 2007 34 731 759 18061816
   PubMed Web of Science ®Google Scholar
• Meneghini L Hermansen K Mersebach H Svendsen A Kumar S Treatment intensification by stepwise addition of prandial insulin aspart to once-daily basal insulin detemir in subjects with type 2 diabetes: the STEPwise™ trial [abstract]. Diabetes 2010 59 Suppl 1
   Google Scholar
• Mayfield JA White RD Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function Am Fam Physician 2004 70 489 500 15317436
   PubMed Web of Science ®Google Scholar
• Harris S Yale JF Dempsey E Gerstein H Can family physicians help patients initiate basal insulin therapy successfully? randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial Can Fam Physician 2008 54 550 558 18411384
   PubMed Web of Science ®Google Scholar
• Raccah D Haak T Huet D Stepwise intensification of prandial insulin versus basal-bolus insulin therapy in patients with type 2 diabetes mellitus [abstract] 47th European Association for the Study of Diabetes Annual Meeting 2010 Abstract 958.
   Google Scholar